🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Very pleased and honored to have had the opportunity to present the first results of our study on META-PRISM, a cohort of > 1,000 very aggressive metastatic tumors. Thanks to Gustave Roussy, Prism Center & CentraleSupélec for making this possible. #ESHG2022

Proud to have been part of this fantastic study and of Papaemmanuil's team! This work contributes to improving our understanding of highly-aggressive AML tumors and hopefully will help medical doctors better assess the risk profile of each patient.

4 yrs ago, we discussed with Mathematicians ⁦CentraleSupélec⁩ about integrating Maths in Cancer Research projects⁩. It’s nice to see papers coming on Mathematical models of cancer from our teams. Here a modeling of myeloproliferative disorders 👇 pnas.org/doi/10.1073/pn…

WES & RNAseq landscape of > 1,000 multi-resistant tumors treated Gustave Roussy highlights the current gap in understanding treatment resistances. Preprint medrxiv.org/cgi/content/sh…. Data will be made available upon release in peer-reviewed journal. CentraleSupélec Prism Center.

Tks anirban ! RNA seq and whole exome in 1000 and 500 pretreated metastatic cancers. Interesting to see the impact of prior therapies, especially platinum, on DNA + discovery of new alterations involved in resistance (PTEN transloc). A huge work from PRISM (maybe futur center🤞)

👉META-PRISM: 1,031 pan-cancer refractory metastatic tumors profiled via whole-exome and transcriptome sequencing. medrxiv.org/content/10.110…

📯 Hear ye! Hear ye! The #TopTweet is presented to thee! 🥂 Congratulations to the team with Drs. Yanis Tazi (@taziyanis) and Ellie Papaemmanuil (Elli Papaemmanuil, PhD) from Memorial Sloan Kettering Cancer Center on the development of an open-access clinical decision support tool! x.com/Hema_News/stat…

Now online in Cancer Discovery: Integrative Pan-cancer Genomic and Transcriptomic Analyses of Refractory #Metastatic Cancer - by ypradat Daniel Gautheret Sergey Nikolaev and colleagues Prism Center Gustave Roussy CentraleSupélec ParisSaclay Inserm aacrjournals.org/cancerdiscover…

Integrative #Pancancer Genomic and Transcriptomic Analyses of Refractory #Metastatic Cancer, by ypradat, Daniel Gautheret, Sergey Nikolev et al. bit.ly/3Yq5XaL Prism Center Gustave Roussy CentraleSupélec ParisSaclay Inserm

#Statistics thought of the day: futility of much high-dimensional omics research (false discovery rates be damned): when N<p there is often no correlation between estimated and actual effects hbiostat.org/bbr/hdata.html…

Now presenting metaPRISM. Come and visit us AACR poster section 31. Gustave Roussy Université Paris-Saclay

We financially and technically supported a pan-TCGA WES analysis in the Cancer Discovery paper "Integrative #Pancancer Genomic and Transcriptomic Analyses of Refractory #Metastatic Cancer" by ypradat, Daniel Gautheret, Sergey Nikolev et al. aacrjournals.org/cancerdiscover… Prism Center Gustave Roussy

.Prism Center selected to receive 30-40 M euros to build a Precision Oncology Center. Vision: to classify pts based on biology. Scientific strategy: bottom-up approach to model cancer biology in each pt (fig 2) for early cancer or relapse detection, & tt optimisation (fig 3).

Very proud to see our work on the pan-cancer comparison of the genomic landscapes of primary and metastatic tumor published in this weeks issue of Nature: nature.com/articles/s4158…. Francisco Martínez-Jiménez Arne Van Hoeck Hartwig Medical @UMCU_CMM Oncode Institute Vall d’Hebron Institute of Oncology (VHIO)

The DAISY trial of T-DXd in MBC with variable HER2 expression is out on Nature Medicine. Many important findings, including a similar ORR with T-DXd in HER2-low (37.5%) & HER2-0 (29.7%) MBC. Congrats to Fernanda Mosele FabriceAndre et al for this impressive work! nature.com/articles/s4159…

1st award ESMO - Eur. Oncology : I Ray-Coquard on rare gyne cancers. How to improve outcome: precise dg (referral), quality of network (infrastructure & scient collab), guidelines adh, inclusion of all stakeholders, database, biomarker driven approvals. Prism Center cited ! #ESMO2023

I am thrilled to announce that I will be supported by a postdoctoral fellowship from Fondation ARC for the next 3y to investigate the molecular features of treatment-related myeloid leukemias. Work under the supervision of Elsa Bernard at Gustave Roussy and part of Prism Center.

Just left #MAP2024 with inspiring talks x current hot topics in oncology! I was very pleased to cross path again with Elli Papaemmanuil, PhD and to attend with colleagues S. Dogan, FabriceAndre, Elsa Bernard from Gustave Roussy. Many thanks to Fondation ARC for the travel grant.